FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884355935> ?p ?o ?g. }

• W2884355935 abstract "Tenofovir disoproxil fumarate (TDF, commonly termed ‘tenofovir’) is the antiretroviral most commonly implicated in antiretroviral-induced nephrotoxicity. As patients on successful antiretroviral therapy (ART) age, their risk for developing renal disease may increase in part because of ART itself, but more importantly, because of HIV-associated and non-HIV-associated comorbidity. Therefore, clinicians need an approach to managing renal disease in people on TDF. TDF as a cause of acute kidney injury (AKI) or chronic kidney disease (CKD) is uncommon, and clinicians should actively exclude other causes (Box 1). In TDF-associated AKI, TDF should be interrupted in all cases, and replaced, or ART interrupted altogether. Tenofovir disoproxil fumarate toxicity can present as AKI or CKD, and as a full or partial Fanconi’s syndrome. TDF has a small but definite negative impact on kidney function (up to a 10% decrease in glomerular filtration rate [GFR]). This occurs because of altered tubular function in those exposed to TDF for treatment and as pre-exposure prophylaxis. Renal function should be assessed using creatinine-based estimated GFR at the time of initiation of TDF, if ART is changed, at 1–3 months, and then ideally every 6–12 months if stable. Specific tests of tubular function are not routinely recommended; in the case of clinical concern, a spot protein or albumin: creatinine ratio is preferable, but in resource-limited settings, urine dipstick can be used. More frequent monitoring may be required in those with established CKD (estimated glomerular filtration rate [eGFR] < 50 mL/min/1.73 m2) or risk factors for kidney disease. The most common risk factors are comorbid hypertension, diabetes, HIV-associated kidney disease, hepatitis B or C co-infection, and TDF in combination with a ritonavir-boosted protease inhibitor. Management of these comorbid conditions must be prioritised in this group. If baseline screening eGFR is < 50 mL/min/1.73 m2, abacavir (the preferred option), and dose-adjusted TDF (useful if concomitant hepatitis B), zidovudine or stavudine (d4T) remain alternatives to full-dose TDF. If there is a rapid decline in kidney function (eGFR drops by more than 25% and decreases to < 50 mL/min/1.73 m2 from of baseline function), or there is new onset or worsening of proteinuria or albuminuria, clinicians should review ART and other potentially nephrotoxic medications and comorbidity and conduct further testing if indicated. If kidney function does not improve after addressing reversible causes of renal failure, then referral to a nephrologist is appropriate. In the case of severe CKD, timeous referral for planning for renal replacement therapy is recommended. Tenofovir alafenamide, a prodrug of tenofovir, appears to have less renal toxicity and is likely to replace TDF in future." @default.
• W2884355935 created "2018-08-03" @default.
• W2884355935 creator A5004669867 @default.
• W2884355935 creator A5017874022 @default.
• W2884355935 creator A5056953136 @default.
• W2884355935 date "2018-07-17" @default.
• W2884355935 modified "2023-10-10" @default.
• W2884355935 title "An overview of tenofovir and renal disease for the HIV-treating clinician" @default.
• W2884355935 cites W131994380 @default.
• W2884355935 cites W1866384176 @default.
• W2884355935 cites W1962312697 @default.
• W2884355935 cites W1967495748 @default.
• W2884355935 cites W1967879506 @default.
• W2884355935 cites W1968789632 @default.
• W2884355935 cites W1970070985 @default.
• W2884355935 cites W1979116787 @default.
• W2884355935 cites W1987415913 @default.
• W2884355935 cites W1988338542 @default.
• W2884355935 cites W1998310232 @default.
• W2884355935 cites W2004567313 @default.
• W2884355935 cites W2005270107 @default.
• W2884355935 cites W2016257631 @default.
• W2884355935 cites W2023206926 @default.
• W2884355935 cites W2029773175 @default.
• W2884355935 cites W2030888755 @default.
• W2884355935 cites W2037565950 @default.
• W2884355935 cites W2053407562 @default.
• W2884355935 cites W2080152031 @default.
• W2884355935 cites W2082914477 @default.
• W2884355935 cites W2087258915 @default.
• W2884355935 cites W2094013521 @default.
• W2884355935 cites W2102223954 @default.
• W2884355935 cites W2102661607 @default.
• W2884355935 cites W2107027814 @default.
• W2884355935 cites W2113525844 @default.
• W2884355935 cites W2118020641 @default.
• W2884355935 cites W2138845948 @default.
• W2884355935 cites W2142285241 @default.
• W2884355935 cites W2148228968 @default.
• W2884355935 cites W2153189426 @default.
• W2884355935 cites W2160095199 @default.
• W2884355935 cites W2162226934 @default.
• W2884355935 cites W2162761942 @default.
• W2884355935 cites W2165446220 @default.
• W2884355935 cites W2168251450 @default.
• W2884355935 cites W2218979693 @default.
• W2884355935 cites W2288781812 @default.
• W2884355935 cites W2467227824 @default.
• W2884355935 cites W2470481127 @default.
• W2884355935 cites W2487468469 @default.
• W2884355935 cites W2519584650 @default.
• W2884355935 cites W2549563205 @default.
• W2884355935 cites W2582602949 @default.
• W2884355935 cites W2586457168 @default.
• W2884355935 cites W2589249894 @default.
• W2884355935 cites W2768442939 @default.
• W2884355935 cites W2889057765 @default.
• W2884355935 cites W3025238321 @default.
• W2884355935 cites W4232704346 @default.
• W2884355935 cites W4298838808 @default.
• W2884355935 cites W587018455 @default.
• W2884355935 doi "https://doi.org/10.4102/sajhivmed.v19i1.817" @default.
• W2884355935 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6111387" @default.
• W2884355935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30167339" @default.
• W2884355935 hasPublicationYear "2018" @default.
• W2884355935 type Work @default.
• W2884355935 sameAs 2884355935 @default.
• W2884355935 citedByCount "26" @default.
• W2884355935 countsByYear W28843559352018 @default.
• W2884355935 countsByYear W28843559352019 @default.
• W2884355935 countsByYear W28843559352020 @default.
• W2884355935 countsByYear W28843559352021 @default.
• W2884355935 countsByYear W28843559352022 @default.
• W2884355935 countsByYear W28843559352023 @default.
• W2884355935 crossrefType "journal-article" @default.
• W2884355935 hasAuthorship W2884355935A5004669867 @default.
• W2884355935 hasAuthorship W2884355935A5017874022 @default.
• W2884355935 hasAuthorship W2884355935A5056953136 @default.
• W2884355935 hasBestOaLocation W28843559351 @default.
• W2884355935 hasConcept C126189478 @default.
• W2884355935 hasConcept C126322002 @default.
• W2884355935 hasConcept C126894567 @default.
• W2884355935 hasConcept C159641895 @default.
• W2884355935 hasConcept C177713679 @default.
• W2884355935 hasConcept C203014093 @default.
• W2884355935 hasConcept C2778653478 @default.
• W2884355935 hasConcept C2779026464 @default.
• W2884355935 hasConcept C2779344132 @default.
• W2884355935 hasConcept C2780091579 @default.
• W2884355935 hasConcept C2780306776 @default.
• W2884355935 hasConcept C2780472472 @default.
• W2884355935 hasConcept C3013748606 @default.
• W2884355935 hasConcept C71924100 @default.
• W2884355935 hasConcept C90924648 @default.
• W2884355935 hasConceptScore W2884355935C126189478 @default.
• W2884355935 hasConceptScore W2884355935C126322002 @default.
• W2884355935 hasConceptScore W2884355935C126894567 @default.
• W2884355935 hasConceptScore W2884355935C159641895 @default.
• W2884355935 hasConceptScore W2884355935C177713679 @default.
• W2884355935 hasConceptScore W2884355935C203014093 @default.

• next